CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
Lampalizumab +1 moredrug
Likely dose
Lampalizumab 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02288559
NCT02288559Phase 2Completed
CompareCT.gov

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy

Genentech, Inc.·interventional·Posted Nov 11, 2014·Updated Sep 25, 2019

In Brief

A Phase 2 clinical trial evaluating Sham and Lampalizumab for Geographic Atrophy. Completed, enrolled 96 participants across 36 sites.

Detailed Summary

This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A safety run-in assessment will be conducted prior to initiating enrollment in the randomized study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 11, 2014
Enrollment StartMar 30, 2015
Primary CompletionJun 2, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.6 years ago

Interventions

Shamother

Sham injection will be administered as a matching intravitreal injection of lampalizumab.

Lampalizumabdrug

10 mg dose of lampalizumab administered intravitreally